Vancomycin-resistant Staphylococcus aureus infection

VRSA refers to infection with Staphylococcus aureus that is resistant to vancomycin, as explicitly described in the source material ^[1][2][3]. The available snippets characterize it as part of the broader problem of antimicrobial resistance affecting S. aureus, rather than as a condition with a fully detailed syndrome profile in the supplied sources ^[2][3]. Source-backed detail on standard case definitions, laboratory criteria beyond resistance status, or formal severity classification is not yet available ^[1][2].

The reported clinical presentation in the available case material included fever and an abdominal abscess after liposuction, with culture results obtained before antibiotic therapy showing VRSA ^[1]. In the intensive-care study, VRSA was identified in blood and sputum samples from critically ill patients, indicating that clinically significant infection may be detected from invasive or respiratory specimens ^[2]. The snippets also note clinical improvement of the abscess after drainage and oral broad-spectrum antibiotics in the case report, but they do not provide a general course, complication profile, or prognosis for VRSA overall ^[1]. Source-backed detail on typical symptom patterns, metastatic complications, or recurrence risk is not yet available ^[1][2].

The provided material documents a first reported post-liposuction case in an Indonesian woman treated in South Korea, and it links the pathogen transfer to medical tourism ^[1]. Another source describes VRSA among 150 blood and sputum samples from intensive care patients, with 19 VRSA isolates in that study population ^[2]. The snippets also state that antibiotic-resistant cases in Southeast Asia are increasing every year, but they do not provide a comprehensive geographic distribution or population burden for VRSA ^[1]. Broader surveillance estimates, endemicity patterns, and risk stratification by region are not yet available from the supplied sources ^[1][2].

The source material does not describe a specific biologic transmission route for VRSA beyond its detection in infected clinical specimens and the implication of transfer associated with medical tourism ^[1][2]. Infection control commentary emphasizes identifying and isolating resistant organisms introduced from outside institutions, which indicates concern for health care-associated spread ^[3]. Source-backed detail on direct contact, environmental persistence, or community transmission is not yet available ^[1][3].

The supplied sources most clearly implicate patients exposed to medical tourism and post-procedural care, as well as critically ill intensive care patients from whom VRSA was isolated in blood and sputum samples ^[1][2]. The infection-control source also highlights organisms introduced from outside institutions, suggesting health care exposure as an important context for risk ^[3]. Source-backed detail on other specific high-risk groups is not yet available in the provided material ^[1][2][3].

Available sources support antimicrobial stewardship and infection-control measures as the main preventive approach, including wise and sparing antibiotic use, avoidance of unnecessary treatment duration, and efforts to identify and isolate resistant organisms introduced from outside institutions ^[3]. The medical-tourism case report also suggests that health care settings should be prepared to encounter resistant infections linked to cross-border care ^[1]. Source-backed detail on decolonization, screening protocols, or procedure-specific prevention measures is not yet available ^[1][3].

In surveillance terms, VRSA should be read as a resistant S. aureus event detected through culture or isolate-based reporting, with particular attention to health care exposure and cross-institutional importation ^[1][3]. The limited sources available here suggest that cases may appear in post-procedural settings or among critically ill patients, but they do not establish a stable incidence pattern for routine monitoring ^[1][2]. Source-backed detail on standardized case ascertainment, trend interpretation, or alert thresholds is not yet available ^[1][2][3].

1. 1 Nelwan EJ et al. Vancomycin-Resistant Staphylococcus Aureus Infection Post-Liposuction in South Korea. Cureus. 2021 Apr 7. PMID: 33987041. doi: 10.7759/cureus.14357. PubMed: https://pubmed.ncbi.nlm.nih.gov/33987041/
2. 2 Elsawy S et al. Effect of silver nanoparticles on vancomycin resistant Staphylococcus aureus infection in critically ill patients. Pathog Glob Health. 2021 Jul. PMID: 33872131. doi: 10.1080/20477724.2021.1914412. PubMed: https://pubmed.ncbi.nlm.nih.gov/33872131/
3. 3 Wenzel RP et al. Vancomycin-resistant Staphylococcus aureus: infection control considerations. Clin Infect Dis. 1998 Aug. PMID: 9709870. doi: 10.1086/514646. PubMed: https://pubmed.ncbi.nlm.nih.gov/9709870/
4. 4 Cefpirome–vancomycin combination in methicillin-resistant Staphylococcus aureus infection. Clinical Microbiology and Infection. 1998. doi: 10.1111/j.1469-0691.1998.tb00663.x. DOI: https://doi.org/10.1111/j.1469-0691.1998.tb00663.x
5. 5 Vancomycin-resistant Staphylococcus aureus. The Lancet. 1998. doi: 10.1016/s0140-6736(05)78596-2. DOI: https://doi.org/10.1016/s0140-6736(05)78596-2
6. 6 Vancomycin-resistant Staphylococcus aureus. The Lancet. 1998. doi: 10.1016/s0140-6736(05)78597-4. DOI: https://doi.org/10.1016/s0140-6736(05)78597-4

ICD-10

ICD-11

Total cases

39

Peak month

2020-01

Coverage

3 reporting countries · 2012-09-14 → 2026-06-20